The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Discovering novel ligands for macromolecules using X-ray crystallographic screening
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Berman, H. M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.235 · Cited by 40,196
[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475
Goodford, P. J. (1985) · Journal of Medicinal Chemistry · doi:10.1021/jm00145a002 · Cited by 2,634
Discovering High-Affinity Ligands for Proteins: SAR by NMR
Shuker, S. B., Hajduk, P. J., Meadows, R. P., & Fesik, S. W. (1996) · Science · doi:10.1126/science.274.5292.1531 · Cited by 2,041
Physiological consequences of loss of plasminogen activator gene function in mice
Carmeliet, P., Schoonjans, L., Kieckens, L., Ream, B., Degen, J., Bronson, R., De Vos, R., van den Oord, J. J., Collen, D., & Mulligan, R. C. (1994) · Nature · doi:10.1038/368419a0 · Cited by 1,037
Structure-Based Strategies for Drug Design and Discovery
Kuntz, I. D. (1992) · Science · doi:10.1126/science.257.5073.1078 · Cited by 989
High-throughput and ultra-high-throughput screening: solution- and cell-based approaches
Sundberg, S. (2000) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(99)00051-8 · Cited by 455
Structure-based drug design: progress, results and challenges
Verlinde, C. L., & Hol, W. G. (1994) · Structure · doi:10.1016/s0969-2126(00)00060-5 · Cited by 331
Structure-Based Molecular Design
Kuntz, I. D., Meng, E. C., & Shoichet, B. K. (1994) · Accounts of Chemical Research · doi:10.1021/ar00041a001 · Cited by 328
The SHAPES strategy: an NMR-based approach for lead generation in drug discovery
Fejzo, J., Lepre, C. A., Peng, J. W., Bemis, G. W., Ajay, Murcko, M. A., & Moore, J. M. (1999) · Chemistry & Biology · doi:10.1016/s1074-5521(00)80022-8 · Cited by 271
Cited by
Improved protein–ligand docking using GOLD
Verdonk, M. L., Cole, J. C., Hartshorn, M. J., Murray, C. W., & Taylor, R. D. (2003) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.10465 · Cited by 3,067
Huntington's disease: from molecular pathogenesis to clinical treatment
Ross, C. A., & Tabrizi, S. J. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70245-3 · Cited by 1,743
Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
Arkin, M. R., & Wells, J. A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1343 · Cited by 1,705
A decade of fragment-based drug design: strategic advances and lessons learned
Hajduk, P. J., & Greer, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2220 · Cited by 1,064
Self-citationNavigating chemical space for biology and medicine
Lipinski, C., & Hopkins, A. (2004) · Nature · doi:10.1038/nature03193 · Cited by 1,002
Awakening guardian angels: drugging the p53 pathway
Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R., & Lane, D. P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2763 · Cited by 881
Rees, D. C., Congreve, Murray, C. W., & Carr, R. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1467 · Cited by 798
Erlanson, D. A., McDowell, R. S., & O'Brien, T. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm040031v · Cited by 642
High-throughput crystallography for lead discovery in drug design
Blundell, T. L., Jhoti, H., & Abell, C. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd706 · Cited by 530
Fragment-Based Approaches in Drug Discovery and Chemical Biology
Scott, D. E., Coyne, A. G., Hudson, S. A., & Abell, C. (2012) · Biochemistry · doi:10.1021/bi3005126 · Cited by 460
Fragment-Based Lead Discovery Using X-ray Crystallography
Hartshorn, M. J., Murray, C. W., Cleasby, A., Frederickson, M., Tickle, I. J., & Jhoti, H. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0495778 · Cited by 422
Application and Limitations of X‐ray Crystallographic Data in Structure‐Based Ligand and Drug Design
Davis, A. M., Teague, S. J., & Kleywegt, G. J. (2003) · Angewandte Chemie International Edition · doi:10.1002/anie.200200539 · Cited by 387
Tethering: Fragment-Based Drug Discovery
Erlanson, D. A., Wells, J. A., & Braisted, A. C. (2004) · Annual Review of Biophysics and Biomolecular Structure · doi:10.1146/annurev.biophys.33.110502.140409 · Cited by 385
Biophysics in drug discovery: impact, challenges and opportunities
Renaud, J.-P., Chung, C.-W., Danielson, U. H., Egner, U., Hennig, M., Hubbard, R. E., & Nar, H. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.123 · Cited by 382
Virtual Screening Using Protein−Ligand Docking: Avoiding Artificial Enrichment
Verdonk, M. L., Berdini, V., Hartshorn, M. J., Mooij, W. T. M., Murray, C. W., Taylor, R. D., & Watson, P. (2004) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci034289q · Cited by 380
Fragment-based lead discovery: leads by design
Carr, R. A. E., Congreve, M., Murray, C. W., & Rees, D. C. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03511-7 · Cited by 343
Keynote review: Structural biology and drug discovery
Congreve, M., Murray, C. W., & Blundell, T. L. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03484-7 · Cited by 338
Theory and Applications of NMR-Based Screening in Pharmaceutical Research
Lepre, C. A., Moore, J. M., & Peng, J. W. (2004) · Chemical Reviews · doi:10.1021/cr030409h · Cited by 322
A surface on the androgen receptor that allosterically regulates coactivator binding
Estébanez-Perpiñá, E., Arnold, L. A., Nguyen, P., Rodrigues, E. D., Mar, E., Bateman, R., Pallai, P., Shokat, K. M., Baxter, J. D., Guy, R. K., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708036104 · Cited by 307
Computational Fragment-Based Binding Site Identification by Ligand Competitive Saturation
Guvench, O., & MacKerell, A. D. (2009) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000435 · Cited by 271
Introduction to Fragment-Based Drug Discovery
Erlanson, D. A. (2011) · Topics in Current Chemistry · doi:10.1007/128_2011_180 · Cited by 259
Hit discovery and hit-to-lead approaches
Keserű, G. M., & Makara, G. M. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.06.016 · Cited by 256
The role of quantum mechanics in structure-based drug design
Raha, K., Peters, M. B., Wang, B., Yu, N., Wollacott, A. M., Westerhoff, L. M., & Merz, K. M. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.07.006 · Cited by 252
Fragment-Based Lead Discovery and Design
Joseph-McCarthy, D., Campbell, A. J., Kern, G., & Moustakas, D. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci400731w · Cited by 129
Targeting Protein–Protein Interactions and Fragment-Based Drug Discovery
Valkov, E., Sharpe, T., Marsh, M., Greive, S., & Hyvönen, M. (2011) · Topics in Current Chemistry · doi:10.1007/128_2011_265 · Cited by 107
Screening-based approaches to identify small molecules that inhibit protein–protein interactions
Choi, S., & Choi, K.-Y. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1280456 · Cited by 29
Protein-Protein Interactions as Drug Targets
Wendt, M. D. (2012) · Topics in Medicinal Chemistry · doi:10.1007/978-3-642-28965-1_1 · Cited by 9
Metadata
- Authors
- Nienaber, V. L., Richardson, P. L., Klighofer, V., Bouska, J. J., Giranda, V. L., & Greer, J.
- Venue
- Nature Biotechnology
- Published
- 2000-10
- Volume
- 18
- Issue
- 10
- Pages
- 1105-1108
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W1502177285
- Cited by
- 322
- References
- 17
- FWCI
- 12.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.